Celator Pharmaceuticals Inc. (CPXX) Has Jumped To A New High On Study Results

Celator Pharmaceuticals Inc. (CPXX) announced after the bell Monday that its Phase 3 trial of VYXEOS Liposome for Injection met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with high-risk acute myeloid leukemia.

from RTT - Hot Stocks http://ift.tt/251X7jM
via IFTTT